Alas, poor Tularik! I knew him, Horatio.
Some disappointment with today's selloff, followed by the Genzyme warning.
On the positive side, there is another conference coming up:
Tularik to Present at the 12th Annual Wachovia Securities Nantucket Equity Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 19, 2002-- Tularik Inc. (Nasdaq:TLRK - News) announced that Corinne Lyle, Tularik's Chief Financial Officer, is scheduled to report on the company's research and clinical programs at the 12th Annual Wachovia Securities Nantucket Equity Conference at the Harbor House Village in Nantucket, Massachusetts on Wednesday, June 26, 2002 beginning at 11:15 AM Eastern Time.
About Tularik
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform spans seven disease-based programs focused on three areas: cancer, immunology and metabolic disease. For more information, visit Tularik's Internet website at www.tularik.com.
--------------------------------------------------------------------------------
Contact:
Tularik Inc.
Traci McCarty, 650/825-7182 (investors/media) |
